Piper Sandler on Compass Therapeutics (CMPX): 'Early '8371 Responses Are Super Interesting'
Tweet Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $12.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
